Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.

Michael E WechslerParameswaran NairBenjamin TerrierBastian WalzArnaud BourdinDavid R W Jayne Alexandra M NanzerFlorence RoufosseLena Börjesson SjöYing FanMaria JisonChristopher McCraeSofia NecanderAnat ShavitClaire WaltonPeter A Merkelnull null

Published in: The New England journal of medicine (2024)

Benralizumab was noninferior to mepolizumab for the induction of remission in patients with relapsing or refractory EGPA. (Funded by AstraZeneca; MANDARA ClinicalTrials.gov number, NCT04157348.).

Keyphrases

disease activity
multiple sclerosis
rheumatoid arthritis
systemic lupus erythematosus
ulcerative colitis
chronic rhinosinusitis